Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 14/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 14/20 | 0.49 |
| ▸ | ITGB7 | P26010 | 12/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4213608 | 0.94 | EGLN1 (0.49) | ITGB1ITGA4ITGB7ITGA5ITGB3 | |
| SCHEMBL4204350 | 0.94 | ITGB1 (0.47) | ITGB1ITGA4ITGB7ITGA5ITGB3 | |
| SCHEMBL4206404 | 0.93 | ITGB1 (0.49) | ITGB1ITGA4ITGB7ITGA5ITGB3 | |
| SCHEMBL4207343 | 0.92 | ITGB1 (0.45) | ITGB1ITGA4ITGB7ITGA5ITGB3 | |
| SCHEMBL4218356 | 0.91 | ITGB1 (0.42) | ITGB1ITGA4ITGB7ITGA5ITGB3 | |
| SCHEMBL4201358 | 0.91 | ITGB1 (0.51) | ITGB1ITGA4ITGB7ITGA5ITGB3 | |
| SCHEMBL4142883 | 0.90 | ITGA4 (0.55) | ITGB1ITGA4ITGB7MAPK1 | |
| SCHEMBL4212488 | 0.90 | ITGB1 (0.52) | ITGB1ITGA4ITGB7ITGA5ITGB3 | |
| SCHEMBL4213599 | 0.90 | ITGB1 (0.51) | ITGB1ITGA4ITGB7ITGA5ITGB3 | |
| SCHEMBL4212479 | 0.89 | ITGB1 (0.52) | ITGB1ITGA4ITGB7ITGA5ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111828-A1 | L-ALANINE DERIVATIVES | ASTRAZENECA AB | 2009-04-30 | — | — | US | claimed |
| US-20090111828-A1 | L-ALANINE DERIVATIVES | ASTRAZENECA AB | 2009-04-30 | — | — | US | disclosed |
| US-20090111828-A1 | L-ALANINE DERIVATIVES | ASTRAZENECA AB | 2009-04-30 | — | — | US | disclosed |
| US-20090111828-A1 | L-ALANINE DERIVATIVES | ASTRAZENECA AB | 2009-04-30 | — | — | US | disclosed |
| WO-2007060409-A1 | L-ALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111828-A1 | L-ALANINE DERIVATIVES | ITGA2B, ITGB1, ITGB5 | ITGB1 2/4885ITGA4 19/4885ITGB7 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.